Breast Cancer Research (Online Edition)

Print ISSN
1465-542X
Electronic ISSN
1465-542X
Publisher
Gale
Article count
90
Free count
0
Free percentage
0.0
PDFs via platforms
Gale

  1. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
    Valentina Silvestri, Daniel Barrowdale, Anna Marie Mulligan, Susan L Neuhausen, Stephen Fox, Beth Y Karlan, Gillian Mitchell, Paul James, Darcy L Thull, Kristin Zorn, Natalie J Carter, Katherine L Nathanson, Susan M Domchek, Timothy Rebbeck, Susan J Ramus, Robert L Nussbaum, Olufunmilayo I Olopade, Johanna Rantala, Sook-Yee Yoon, Maria A Caligo, Laura Spugnesi, Anders Bojesen, Inge Sokilde Pedersen, Mads Thomassen, Uffe Birk Jensen, Amanda Ewart Toland, Leigha Senter, Irene L Andrulis, Gord Glendon, Peter J Hulick, Evgeny N Imyanitov, Mark H Greene, Phuong L Mai, Christian F Singer, Christine Rappaport-Fuerhauser, Gero Kramer, Joseph Vijai, Kenneth Offit, Mark Robson, Anne Lincoln, Lauren Jacobs, Eva Machackova, Lenka Foretova, Marie Navratilova, Petra Vasickova, Fergus J Couch, Emily Hallberg, Kathryn J Ruddy, Priyanka Sharma, Sung-Won Kim, Manuel R Teixeira, Pedro Pinto, Marco Montagna, Laura Matricardi, Adalgeir Arason, Oskar Th Johannsson, Rosa Barkardottir, Anna Jakubowska, Jan Lubinski, Angel Izquierdo, Miguel Angel Pujana, Judith Balmaña, Orland Diez, Gabriella Ivady, Janos Papp, Edith Olah, Ava Kwong, Heli Nevanlinna, Kristiina Aittomäki, Pedro Perez Segura, Trinidad Caldes, Tom Van Maerken, Bruce Poppe, Kathleen B M Claes, Claudine Isaacs, Camille Elan, Christine Lasset, Dominique Stoppa-Lyonnet, Laure Barjhoux, Muriel Belotti, Alfons Meindl, Andrea Gehrig, Christian Sutter, Christoph Engel, Dieter Niederacher, Doris Steinemann, Eric Hahnen, Karin Kast, Norbert Arnold, Raymonda Varon-Mateeva, Dorothea Wand, Andrew K Godwin, D Gareth Evans, Debra Frost, Jo Perkins, Julian Adlard, Louise Izatt, Radka Platte, Ros Eeles, Steve Ellis, Ute Hamann, Judy Garber, Florentia Fostira, George Fountzilas, Barbara Pasini, Giuseppe Giannini, Piera Rizzolo, Antonio Russo, Laura Cortesi, Laura Papi, Liliana Varesco, Domenico Palli, Ines Zanna, Antonella Savarese, Paolo Radice, Siranoush Manoukian, Bernard Peissel, Monica Barile, Bernardo Bonanni, Alessandra Viel, Valeria Pensotti, Stefania Tommasi, Paolo Peterlongo, Jeffrey N Weitzel, Ana Osorio, Javier Benitez, Lesley McGuffog, Sue Healey, Anne-Marie Gerdes, Bent Ejlertsen, Thomas V O Hansen, Linda Steele, Yuan Chun Ding, Nadine Tung, Ramunas Janavicius, David E Goldgar, Saundra Buys, Mary B Daly, Anita Bane, Mary Beth Terry, Esther M John, Melissa Southey, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, and Laura Ottini

    Breast Cancer Research (Online Edition) 18(1):15 (2016) PMID 26857456 PMCID PMC4746828

    BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA...
  2. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.

    Breast Cancer Research (Online Edition) 18(1):47 (2016) PMID 27160733 PMCID PMC4862233

    The incidence of ductal carcinoma in situ (DCIS) has rapidly increased over time. The malignant potential of DCIS is dependent on its differentiation grade. Our aim is to determine the distribution of different grades of DCIS among women screened in the mass screening programme, and women not sc...
  3. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer.

    Breast Cancer Research (Online Edition) 18(1):10 (2016) PMID 26810608 PMCID PMC4727393

    Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health remain main...
  4. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode.

    Breast Cancer Research (Online Edition) 18(1):29 (2016) PMID 26956474 PMCID PMC4782371

    Somatostatin (SST) and cortistatin (CORT), two structurally and functionally related peptides, share a family of widespread receptors (sst1-5) to exert apparently similar biological actions, including endocrine/metabolic regulation and suppression of tumor cell proliferation. However, despite th...
  5. Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation.

    Breast Cancer Research (Online Edition) 18(1):38 (2016) PMID 27036297 PMCID PMC4818388

    Targeting the TGF-β1 pathway for breast cancer metastasis therapy has become an attractive strategy. We have previously demonstrated that naringenin significantly reduced TGF-β1 levels in bleomycin-induced lung fibrosis and effectively prevented pulmonary metastases of tumors. This raised the qu...
  6. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.

    Breast Cancer Research (Online Edition) 18(1):2 (2016) PMID 26728598 PMCID PMC4700603

    Dysregulated receptor tyrosine kinase (RTK) signaling is a common occurrence in basal-like and triple-negative breast cancer (BTBC). As a result, RTK-targeting therapies have been initiated but proved difficult, mainly owing to the multiplicity of dysregulated RTKs. Hence, targeting master regul...
  7. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

    Breast Cancer Research (Online Edition) 18(1):3 (2016) PMID 26738606 PMCID PMC4702399

    The insulin-like growth factor 1 (IGF-1) pathway is involved in cell growth and proliferation and is associated with tumorigenesis and therapy resistance. This study aims to elucidate whether variation in the IGF-1 pathway is predictive for pathologic response in early HER2 negative breast cance...
  8. ELF5 isoform expression is tissue-specific and significantly altered in cancer.

    Breast Cancer Research (Online Edition) 18(1):4 (2016) PMID 26738740 PMCID PMC4704400

    E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particu...
  9. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.

    Breast Cancer Research (Online Edition) 18(1):16 (2016) PMID 26852132 PMCID PMC4744406

    Drug resistance in breast cancer is the major obstacle to effective treatment with chemotherapy. While upregulation of multidrug resistance genes is an important component of drug resistance mechanisms in vitro, their clinical relevance remains to be determined. Therefore, identifying pathways t...
  10. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

    Breast Cancer Research (Online Edition) 18(1):17 (2016) PMID 26857361 PMCID PMC4746893

    Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women. Our understanding of the molecular heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in b...
  11. LIN7A is a major determinant of cell-polarity defects in breast carcinomas.

    Breast Cancer Research (Online Edition) 18(1):23 (2016) PMID 26887652 PMCID PMC4756502

    Polarity defects are a hallmark of most carcinomas. Cells from invasive micropapillary carcinomas (IMPCs) of the breast are characterized by a striking cell polarity inversion and represent an interesting model for the analysis of polarity abnormalities. In-depth investigation of polarity protei...
  12. Growth of human breast tissues from patient cells in 3D hydrogel scaffolds.

    Breast Cancer Research (Online Edition) 18(1):19 (2016) PMID 26926363 PMCID PMC4772689

    Three-dimensional (3D) cultures have proven invaluable for expanding human tissues for basic research and clinical applications. In both contexts, 3D cultures are most useful when they (1) support the outgrowth of tissues from primary human cells that have not been immortalized through extensive...
  13. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.

    Breast Cancer Research (Online Edition) 18(1):27 (2016) PMID 26923702 PMCID PMC4770527

    Aberrant DNA methylation is frequently observed in breast cancer. However, the relationship between methylation patterns and the heterogeneity of breast cancer has not been comprehensively characterized. Whole-genome DNA methylation analysis using Illumina Infinium HumanMethylation450 BeadChip a...
  14. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.

    Breast Cancer Research (Online Edition) 18(1):6 (2016) PMID 26757880 PMCID PMC4711100

    Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently,...
  15. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.

    Breast Cancer Research (Online Edition) 18(1):43 (2016) PMID 27117582 PMCID PMC4847231

    A better understanding of immune response in breast cancer brain metastases (BCBM) may prompt new preventive and therapeutic strategies. Immunohistochemical expression of stromal tumor-infiltrating lymphocytes (TILs: CD4, CD8, CTLA4), macrophage/microglial cells (CD68), programmed cell death pro...
  16. Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment.

    Breast Cancer Research (Online Edition) 18(1):49 (2016) PMID 27169366 PMCID PMC4864897

    High mammographic density has been correlated with a 4-fold to 6-fold increased risk of developing breast cancer, and is associated with increased stromal deposition of extracellular matrix proteins, including collagen I. The molecular and cellular mechanisms responsible for high breast tissue d...
  17. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.

    Breast Cancer Research (Online Edition) 18(1):58 (2016) PMID 27246191 PMCID PMC4888666

    Therapies targeting estrogenic stimulation in estrogen receptor-positive (ER+) breast cancer (BC) reduce mortality, but resistance remains a major clinical problem. Molecular studies have shown few high-frequency mutations to be associated with endocrine resistance. In contrast, expression profi...
  18. Intermittent energy restriction induces changes in breast gene expression and systemic metabolism.

    Breast Cancer Research (Online Edition) 18(1):57 (2016) PMID 27233359 PMCID PMC4884347

    Observational studies suggest weight loss and energy restriction reduce breast cancer risk. Intermittent energy restriction (IER) reduces weight to the same extent as, or more than equivalent continuous energy restriction (CER) but the effects of IER on normal breast tissue and systemic metaboli...
  19. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.

    Breast Cancer Research (Online Edition) 18(1):25 (2016) PMID 26897526 PMCID PMC4761146

    Inflammatory breast cancer (IBC) is a very aggressive and lethal subtype of breast cancer that accounts for about 4 % of all breast cancers diagnosed in the United States. Despite the efforts of several investigators to identify the molecular factors driving the aggressive phenotype of IBC, a gr...
  20. Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study.

    Breast Cancer Research (Online Edition) 18(1):42 (2016) PMID 27113363 PMCID PMC4845425

    Molecular breast imaging (MBI) is a functional test used for supplemental screening of women with mammographically dense breasts. Additionally, MBI depicts variable levels of background parenchymal uptake (BPU) within nonmalignant, dense fibroglandular tissue. We investigated whether BPU is a ri...